Vericel Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Vericel Corp 公司

Vericel Corporation 是一家完全整合的商业阶段生物制药公司。该公司为运动医学和严重烧伤护理市场提供先进疗法。它在美国销售三种产品。MACI（猪胶原膜上的自体培养软骨细胞）是一种自体细胞化支架产品，用于修复成人有症状的、一个或多个全层膝关节软骨缺损（无论是否涉及骨骼）。Epicel（培养的自体表皮移植）是一种永久性皮肤替代品，用于治疗深层真皮或全层烧伤面积大于或等于全身表面积 30% 的患者。该公司还持有 NexoBrid（anacaulase-bcdb）的北美权利许可，这是一种含有蛋白水解酶的生物孤儿产品，用于去除成人深层部分厚度和/或全层烧伤的焦痂。

公司简介

公司代码VCEL

公司名称Vericel Corp

上市日期Feb 04, 1997

成立日期1989

CEOMr. Dominick C. Colangelo

员工数量357

证券类型Ordinary Share

年结日Feb 04

公司地址64 Sidney St

城市CAMBRIDGE

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编02139

电话17349305555

网址https://vcel.com/

公司代码VCEL

上市日期Feb 04, 1997

成立日期1989

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

Mr. Kevin F. Mclaughlin

Independent Director

15.10K

--

Ms. Lisa Wright

Independent Director

12.65K

+33.86%

Mr. Sean C. Flynn

Chief Legal Officer

971.00

+105.29%

Ms. Heidi M. Hagen

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

地区USD

名称

营收

占比

United States

52.60M

100.00%

业务

地区

业务USD

名称

营收

占比

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

股东统计

更新时间: 4月20日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

股东类型

持股股东

占比

Investment Advisor

54.79%

Investment Advisor/Hedge Fund

45.86%

Pension Fund

2.91%

Research Firm

2.86%

Hedge Fund

1.09%

Individual Investor

1.06%

Bank and Trust

0.92%

Insurance Company

0.10%

Sovereign Wealth Fund

0.06%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

533

54.94M

109.13%

-1.35M

2025Q1

559

55.34M

109.94%

-1.25M

2024Q4

543

54.07M

108.22%

-1.11M

2024Q3

519

52.64M

107.39%

-2.94M

2024Q2

509

52.53M

108.12%

-3.27M

2024Q1

499

52.78M

109.13%

-3.92M

2023Q4

473

53.52M

112.14%

-4.39M

2023Q3

463

53.25M

111.77%

-4.17M

2023Q2

465

51.63M

108.55%

-6.73M

2023Q1

480

52.04M

109.66%

-6.96M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

7.26M

14.43%

-231.46K

-3.09%

Mar 31, 2025

The Vanguard Group, Inc.

3.48M

6.92%

+6.84K

+0.20%

Mar 31, 2025

Brown Capital Management, LLC

2.88M

5.72%

-353.58K

-10.93%

Mar 31, 2025

State Street Global Advisors (US)

2.44M

4.84%

+32.41K

+1.35%

Mar 31, 2025

Fidelity Management & Research Company LLC

2.19M

4.35%

+146.00K

+7.15%

Mar 31, 2025

Conestoga Capital Advisors, LLC

2.06M

4.1%

-7.83K

-0.38%

Mar 31, 2025

Invesco Advisers, Inc.

1.98M

3.94%

+60.96K

+3.17%

Mar 31, 2025

Congress Asset Management Company, LLP

1.48M

2.93%

+22.58K

+1.55%

Mar 31, 2025

GW&K Investment Management, LLC

1.43M

2.85%

+158.47K

+12.44%

Mar 31, 2025

Geneva Capital Management LLC

1.37M

2.71%

+265.96K

+24.18%

Mar 31, 2025

持股ETF

更新时间: 7月6日周日

机构名称

占比

ALPS Medical Breakthroughs ETF

1.8%

Invesco S&P SmallCap Health Care ETF

1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

1.2%

SPDR S&P Biotech ETF

0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

0.45%

First Trust NASDAQ Pharmaceuticals ETF

0.45%

OneAscent Small Cap Core ETF

0.34%

SPDR S&P 600 Small Cap Growth ETF

0.32%

WisdomTree US SmallCap Quality Growth Fund

0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.32%

ALPS Medical Breakthroughs ETF

占比1.8%

Invesco S&P SmallCap Health Care ETF

占比1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

占比1.2%

SPDR S&P Biotech ETF

占比0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

占比0.45%

First Trust NASDAQ Pharmaceuticals ETF

占比0.45%

OneAscent Small Cap Core ETF

占比0.34%

SPDR S&P 600 Small Cap Growth ETF

占比0.32%

WisdomTree US SmallCap Quality Growth Fund

占比0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

占比0.32%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Vericel Corp

36.260USD

Vericel Corp

36.260

概览

公司

财务